Handa Pharmaceuticals, Inc. (TPEX:6620)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
75.30
-1.10 (-1.44%)
Apr 24, 2025, 1:40 PM CST
-39.76%
Market Cap 12.09B
Revenue (ttm) 972.97M
Net Income (ttm) 452.32M
Shares Out 158.25M
EPS (ttm) 3.24
PE Ratio 23.56
Forward PE 4.78
Dividend 1.00 (1.35%)
Ex-Dividend Date n/a
Volume 171,508
Average Volume 612,362
Open 76.00
Previous Close 76.40
Day's Range 74.90 - 76.20
52-Week Range 49.90 - 145.50
Beta 0.98
RSI 48.94
Earnings Date Apr 2, 2025

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis a... [Read more]

Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6620
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.